Genetics of supraventricular tachycardia: current evidence with a focus on translational relevance and personalized medicine - Scorecard - MDSpire

Genetics of supraventricular tachycardia: current evidence with a focus on translational relevance and personalized medicine

  • By

  • Amin Esmailian

  • Mohammad Alasti

  • May 29, 2026

  • 0 min

Share

Clinical Scorecard: Genetic Factors in Supraventricular Tachycardia: An Overview of Current Research Emphasizing Translational Applications and Personalized Approaches

At a Glance

CategoryDetail
ConditionSupraventricular Tachycardia (SVT)
Key MechanismsInherited susceptibility, genetic factors, polygenic/oligogenic susceptibility, genotype-to-substrate relationships.
Target PopulationPatients with SVT, particularly those with early-onset, familial, or cardiomyopathy-overlap presentations.
Care SettingClinical practice, emergency departments, outpatient electrophysiology referrals, catheter ablation procedures.

Key Highlights

  • SVTs are common arrhythmias with significant morbidity despite low mortality.
  • Genetic architecture varies by SVT subtype, with specific genes implicated in AVNRT and accessory pathway-mediated AVRT/WPW.
  • Current clinical utility of genetics is highest in syndromic and cardiomyopathy-associated SVT.
  • Routine genetic testing is not indicated for most isolated SVT cases.
  • Phenotype-guided evaluation may enable targeted, patient-centered personalization.

Guideline-Based Recommendations

Diagnosis

  • Diagnosis relies on electrocardiographic documentation and ambulatory rhythm monitoring.

Management

  • Catheter ablation is effective for many SVT subtypes, achieving high success rates.

Monitoring & Follow-up

  • Consideration of arrhythmia burden and coexisting structural or genetic heart disease.

Risks

  • SVTs can lead to recurrent palpitations, syncope, impaired exercise tolerance, and anxiety.

Patient & Prescribing Data

Patients with SVT, particularly those with familial or syndromic presentations.

Genetic discoveries may refine SVT risk stratification and inform therapeutic decision-making.

Clinical Best Practices

  • Implement phenotype-first evaluation and targeted testing strategies.
  • Utilize rigorous variant interpretation and multidisciplinary governance.

Related Resources & Content

Original Source(s)

Related Content